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of novel vesicular nanocarriers: ethosomes and ultradeformable liposomes, containing clotrimazole
(CLT), an anti-fungal bioactive. The ethosomal formulation (ET4) and ultradeformable liposomal
(UL) formulation (TT3) showed highest entrapment 68.73 ± 1.4% and 55.51 ± 1.7%, optimal
nanometric size range 132 ± 9.5 nm and 121 ± 9.7 nm, and smallest polydispersity index
0.027 ± 0.011 and 0.067 ± 0.009, respectively. The formulation ET4 provided enhanced transder-
mal ﬂux 56.25 ± 5.49 lg/cm2/h and decreased the lag time of 0.9 h in comparison to TT3 formula-
tion (50.16 ± 3.84 lg/cm2/h; 1.0 h). Skin interaction and FT-IR studies revealed greater penetration
enhancing effect of ET4 than TT3 formulation. ET4 formulation also had the highest zone of inhibi-
tion (34.6 ± 0.57 mm), in contrast to TT3 formulation (29.6 ± 0.57 mm) and marketed cream for-
mulation (19.0 ± 1.00 mm) against candidal species. Results suggested ethosomes to be the most
proﬁcient carrier system for dermal and transdermal delivery of clotrimazole.
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162 R.G.S. Maheshwari et al.1. Introduction
Candidiasis, commonly referred to as yeast infection, is a
fungal infection of any of the Candida species, among them
Candida albicans being the chief ones (Robin et al., 1995).
Clotrimazole, 1-((2-chlorophenyl) diphenylmethyl)-1H-imidaz-
ole (CLT) is a broad-spectrum antifungal bioactive like other
antimycotic imidazoles that interfere with the ergosterol bio-
synthesis in a concentration-dependent fashion and thereby
causing an alteration of the permeability of cell walls. Its
spectrum of efﬁcacy covers all human pathogenic non-invasive
fungi including dermatophytes (species of microsporum, trich-
ophyton, and epidermophyton) and yeasts Candida group.
Apart from that it is the most commonly prescribed topical
antifungal in the United Kingdom for the treatment of tinea
pedis. It has a recommended dose or two to three times daily
(Steven and James, 1999; Tomohiro et al., 2007; Heinrich,
1978).
The oral administration of the CLT is highly prone toward
drug interactions along with low bioavailability and its log P
value (3.5), and pKa (6.7) permits its transdermal application
also (Pandey et al., 2005; Jacobsen et al., 1999; Silva et al.,
1998; Khashaba et al., 2000). Although the skin serves as an
efﬁcient route for the administration of a number of active
ingredients, stratum corneum continues to present drug deliv-
ery constraints because of its formidable barrier nature.
Molecular weight as well as water solubility of CLT (344.85
D and practically insoluble; respectively) also play a key role
that limits the skin delivery of this drug (Mitragotri, 2000;
Hashiguchi et al., 1998; Pedersen et al., 1998).
Recently, the techniques like nanoencapsulation, thermo-
sensitive gel formulation, and bio-adhesion, have been success-
fully engaged to enhance transdermal delivery of CLT (Pandey
et al., 2005; Bilensoy et al., 2006; Pavelic et al., 2005).
Modern approaches for drug delivery via skin have resulted
in the design of modiﬁed liposomes. In this context; nowadays
considerable attention has been given to vesicular approaches
viz: ultradeformable liposomes (often referred to as ‘Transfer-
somes’) and ethosomes. Basically these approaches use the
non-toxic and biodegradable, characteristic of phospholipid
and for this reason they are able to prolong the half-life of a
drug to attain a sustained-release effect. On the other hand,
previous studies demonstrated that phospholipids can exhibit
their enhancing effect on the skin in the presence of organic
solvents such as ethanol (as in the case of ethosomes) and
surfactants such as span-80 (as in the case of ultradeformable
liposomes). These features make these formulations more
advantageous over the liposomes, solutions and creams in
terms of skin penetration and therapeutic effects. Moreover,
reports on the transdermal delivery of therapeutic agents via
ethosomal and ultradeformable liposomal vesicles have been
encouraging (Touitou et al., 2000; Jain et al., 2004; Paolino
et al., 2005a,b; Elsayed et al., 2006; Paul et al., 1998).
Ultradeformable liposomes consist of phospholipids, an
edge activator that increases deformability of the bilayers by
destabilizing them and are elastic in nature (Cevc et al.,
2002). Ethosomal systems, comprising of phospholipids,
ethanol and water, have been reported to improve skin pene-
tration of several drugs (Touitou et al., 2000; Jain et al.,
2004; Paolino et al., 2005a,b). The present work thus, empha-
sizes on the formulation, development and generation of com-parative data on transdermal penetration as well as therapeutic
efﬁcacy of CLT, thereby, mediating the two novel vesicular
approaches.
2. Materials and methods
2.1. Materials
Soybean phosphatidylcholine (Phospholipon–90(H))
(Natterman Phospholipids GMBH, Germany) contained
93.63% phosphatidylcholine. Clotrimazole (Zenith Pharma-
ceuticals, India) All other chemicals were of HPLC grade
and used without further modiﬁcation.
2.2. Preparation of CLT loaded ethosomes
Ethosomes were prepared by mechanical-dispersion method, as
reported and described earlier (Lopez-Pinto et al., 2005; Dubey
et al., 2007a,b). Brieﬂy, in a completely dried round bottomed
ﬂask (RBF) Phospholipon-90(H) in varying concentrations,
(Table 1) was dissolved in a mixture of chloroform and metha-
nol (2:1 v/v). A thin lipid ﬁlm was then formed on the wall of
the RBF using Rotavapour (DB-31355, DICIBEL instruments,
India), by maintaining the temperature above the lipid transi-
tion temperature (55 ± 2 C) and the organic solvent was com-
pletely evaporated by vacuum, followed by hydration (6 h) with
different concentrations (15%, 25%, 35%, 45% w/v of ethanol
in water) of hydroethanolic mixture containing CLT (1.0%w/v).
The preparations were further subjected to sonication for 3
cycles of 5 min at each 5 min interval.
2.3. Preparation of CLT loaded ultradeformable liposomes
For the preparation of ultradeformable liposomes, mechani-
cal-dispersion method was followed as described earlier
(Elsayed et al., 2006; Mahor et al., 2007). Phospholipon-
90(H) (85 parts) and the varying parts of Span-80 (5/10/15/
20) were dissolved in an organic solvent mixture (methanol
and chloroform in the ratio of 2:1) along with CLT (1.0%
w/v). A thin lipid ﬁlm was formed on the wall of the RBF
and was hydrated with Phosphate buffer pH 7.4 to make a
ﬁnal suspension concentration of 10 mg/ml. The preparations
were further subjected to sonication for 3 cycles of 5 min at
each 5 min interval. Furthermore, the ethosomal and ultrade-
formable liposomal formulations were optimized on the basis
of entrapment efﬁciency and vesicle size (Table 1).
2.4. Size distribution measurement
Vesicle size distributions of ethosomal andUL formulationswere
measured in two sets of triplicates in a multimodal mode. The
techniqueoptedwasDynamicLight Scattering (DLS) using com-
puterized Malvern Autosizer 5002 inspection system (Malvern,
UK). Prior to the measurement, formulations were mixed with
the PBS, pH 7.4 and the measurements were taken in triplicate.
2.5. Entrapment efﬁciency
Entrapment efﬁciencies of ethosomal and ultradeformable
liposomes (UL) formulations were measured using Sephadex
Table 1 Composition and optimization parameters of various Ethosomal and UL formulations.
Formulations Composition Vesicle size (nm) PI %EE
P:E (%w/v) S:P (%w/v)
ET1 15:3 – 163 ± 13 0.066 ± 0.029 28.4 ± 1.2
ET2 25:3 – 152 ± 11 0.052 ± 0.021 36.3 ± 2.1
ET3 35:3 – 144 ± 10 0.050 ± 0.019 48.7 ± 3.4
ET4 45:3 – 132 ± 9.5 0.279 ± 0.011 68.7 ± 1.4
TT1 – 5:85 157 ± 8.7 0.087 ± 0.017 32.6 ± 12
TT2 – 10:85 143 ± 11 0.073 ± 0.013 45.8 ± 3.8
TT3 – 15:85 121 ± 9.7 0.067 ± 0.009 65.5 ± 1.7
TT4 – 20:85 184 ± 12 0.095 ± 0.016 42.3 ± 1.4
Note: P:E, Phospholipid:Ethanol (% w/v); S:P, Span-80:Phospholipid: (% w/v); PI, polydispersity index; EE, entrapment efﬁciency.
Ethosomal formulations (ET1–ET4).
Ultradeformable liposomal formulations (TT1–TT4).
Values are represented as mean ± SD (n= 3).
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Sorensen et al., 1977) For this the formulations that were kept
overnight at 4 C were spun in an ultracentrifuge at 3000 rpm
for 1 h (Ultracentrifuge, Hitachi, Singapore). Columns were
prepared by allowing 10 g of Sephadex G-50 to swell overnight
in 120 ml of 0.9% NaCl solution (Nguyen et al., 1999). Triton
X-100 (0.5% w/w) was used as the lysing agent and entrap-
ment efﬁciency of the drug was calculated using HPLC
(Model; LC-10ATVP: Column; Luna 5U C18 100 A; Shimadzu,
Kyoto, Japan) using acetonitrile:water (50:50) as a mobile
phase at a ﬂow rate of 0.5 ml/min with Twenty microliter injec-
tion volume.%. Entrapment efﬁciency was then calculated
using Eq. (1):
Entrapment efficiencyð%Þ¼ Mass of drug in vesicles
Mass of drug used in formulation
100
ð1Þ2.6. Transmission electron microscopy
For Transmission Electron Microscopy (TEM; Philips CM12
Electron Microscope, Netherlands), the samples were nega-
tively stained with a 1% w/v aqueous solution of phospho-
tungustic acid (PTA) prior to use. Negatively stained
samples were examined at an accelerated voltage of 20 kV with
a magniﬁcation of ·4000.
2.7. Atomic force microscopy (AFM)
In addition to the above mentioned electron microscopic stud-
ies, both of the formulations were also analyzed for topogra-
phy of the sample surface by Digital Instruments, USA
Nanoscope E. For AFM study, one drop of each formulation
was spread out homogenously on a separate glass piece
(4 mm · 4 mm), and imaging was carried out at a scan speed
of 10.17 Hz with ·4000 magniﬁcation (Ruozi et al., 2007;
Sriamornsak et al., 2008).
2.8. Skin permeation studies
Franz diffusion cell was used to determine the in vitro skin per-
meation of CLT loaded ethosomal and UL formulations.Effective permeation area, receptor cell volume, receptor com-
partment media and temperature were kept 1.0 cm2, 10 ml,
Phosphate buffer (pH 7.4) and 37 ± 1 C, respectively. The
abdominal portion of a rat (Male Sprague Dawley, 4–5 week
old, 100–120 g) was used in the study. After clean shaving,
washing and sectioning, the skin was ﬁxed on a receptor com-
partment (stratum corneum side facing upward into the donor
compartment). The ET4 formulation and TT3 formulation
(250 ll) were applied separately on the donor compartment.
Samples (250 ll) were collected at 2, 4, 6, 8, 12, 18, 24 h inter-
vals and analyzed by HPLC (Shimadzu, Model; LC-10ATVP:
Column; Luna 5U C18 (2) 100 A, Kyoto, Japan). Hydroethan-
olic CLT solution (1% w/v drug dispersed in 45% hydroethan-
olic solution) and pure drug solution (1% w/v CLT in water)
were also studied to generate comparative data. The cumula-
tive amount of drug permeated per unit area was plotted as
a function of time. From this plot, the steady-state permeation
rate (Jss) and lag time (h) were calculated from the slope and x
intercept of the linear portion, respectively. Experiments were
repeated thrice for each formulation (n= 3).
All investigations were performed as per the protocol
approved by CSPCSE (Registration No. 465/01/ab/CPCSEA;
Letter No. IAEC/IPSA/COP/09/2008).
2.9. Vesicle skin interaction studies
The vesicle skin interaction study was done on the basis of
structural changes in stratum corneum, epidermis and dermis.
ET4 and TT3 formulations were applied topically on the skin
of rats (Male Sprague Dawley, 4–5 week old, 90–100 g) for
8 h. After sacriﬁcing the animals by ether inhalation, skin
was excised and stored in formalin solution (10% w/v). For
the study, thick sections were cut from prepared blocks and
subjected to optical microscopy. Similar procedure was fol-
lowed to prepare control skin section, except the treatment
by hydroalcoholic solution instead of ET4 and TT3
formulations.
2.10. Evaluation of bilayer ﬂuidity using FT-IR spectroscopy
The whole skin, epidermis and stratum corneum were pre-
pared by the method earlier reported (Panchagnula et al.,
2001; Scott et al., 1986). Brieﬂy, the male rat (Sprague–
164 R.G.S. Maheshwari et al.Dawley, 4–5 week old, 100–120 g) was sacriﬁced and after
hair removal, the dorsal skin was excised, washed with water
and the subcutaneous tissue was removed surgically. After
washing with phosphate buffer, the skin was defrosted
(20 C), till used. The epidermis was prepared by treating
the skin with 1 M sodium bromide solution in water for
12 h. Stratum corneum was separated from the epidermis
using 0.1% w/v trypsin solution in water for 12 h (stratum
corneum side facing upward) (Yokomizo, 1996; Scott
et al., 1986; Panchagnula et al., 2001). Finally the stratum
corneum sheets were dried in a desiccator till completely
dried. On the day of the experiment, stratum corneum sheets
were treated with ET4 formulation, TT3 formulation and
hydroethanolic solution (30% ethanol) for 8 h. The treated
sheets were dried and investigated by FT-IR spectrophotom-
eter (IR 200; DTGS detector; Thermo Nicolet, USA)
between 4000 and 1000 cm1.
2.11. In vitro anticandidal testing
Standard disk diffusion method as reported earlier (Ingroff,
2007), was followed for in vitro anticandidal testing, and
C. albicans (ATCC No. 90028) was used as an indicator strain.
The culture medium selected for this purpose was Sabouraud
Dextrose Agar (SDA; HiMedia Laboratories Pvt. Ltd., Mum-
bai, India) and the ﬁnal pH of the medium was kept at
5.6 ± 0.2 to retard the growth of unlike organisms. The med-
ium was sterilized using an autoclave at 121 C for 20 min.
Freshly prepared culture (24 h) was used for inoculum prepara-
tion, which was prepared by suspending 1–2 colonies in tubes
containing SDA media and 10 ml of sterile saline (0.9% w/v
NaCl solution). The turbidity was adjusted to match 0.5 on
the McFarland scale (indicating approximately 107 cells/ml).
Petri dishes (9 cm-diameter) containing medium to a depth of
5 mm were used. The inoculum (0.5 ml) was spread over the
surface of SDA media and after appropriate solidiﬁcation (atFigure 1A Photomicrograph of ET4 formulation as35 ± 2 C for 10 min), ethosomal formulation (Test I, ET4)
and UL formulation (Test II, TT3) along with control (mar-
keted cream formulation) (all equivalent to clotrimazole 1%
w/v) were applied. The complete experiment was carried out
in a sterile area (sterile laminar air ﬂow hood). Finally, the
petri plates were incubated at 37 ± 2 C for 24 h in reverse
position. The zone of inhibition (mm of diameter) was calculated
(Carrillo-Munoz et al., 2002; Ahmed et al., 1998).
2.12. Statistical analysis
Statistical analysis was performed with Graph Pad Instat
Software (version 3.0, Graph Pad Software San Diego,
California, USA) using one-way ANOVA followed by
Tukey–Kramer multiple comparison test. Difference with
P> 0.05 was considered statistically insigniﬁcant, whereas
P< 0.001 was considered extremely signiﬁcant.
3. Results
3.1. % Entrapment efﬁciency (EE%)
Enormous capability to entrap CLT in lipid bilayer structure
was observed with ET4 formulation (68.73 ± 1.4%), larger
than TT3 formulation (55.51 ± 1.7%). These outcomes elicit
the potential of ethosomal carrier system to load as well as
deliver CLT at its required therapeutic window.
3.2. Vesicular characterization using TEM
The ethosome and ultradeformable liposome based formula-
tions when visualized by TEM and analyzed by analysis soft-
ware (Soft Imaging System GmbH, Munster, Germany),
exhibited spherical shape mostly with unilamellar pattern,
and thereby conﬁrm their vesicular characteristics (Figs. 1Aseen by TEM (transmission electron microscopy).
Figure 1B Photomicrograph of TT3 formulation as seen by
TEM (transmission electron microscopy).
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methods.
3.3. Atomic force microscopy
When the ET4 formulation was examined by AFM, spherical
structure of the small unilamellar vesicles was observed. The
size of the ethosomal formulation was measured from the
AFM images. The geometric mean diameter and height were
128 ± 10.5 nm and 7.8 ± 1.2 nm respectively. Similarly theFigure 2A Photomicrographs of ET4 formulatiogeometric mean diameter and height of the TT3 formulation
were found to be 120 ± 9.3 nm and 5.5 ± 1.1 nm respectively
(Figs. 2A and B).
3.4. Skin permeation studies
The investigation of transport enhancement ability of ET4 and
TT3 formulations was measured using the abdominal portion
of a rat and the method adapted was Franz diffusion cell mea-
surement. The cumulative amount of CLT permeated per unit
area across excised rat skin as the function of time (Fig. 3),
steady-state transdermal ﬂux and lag time were determined.
The steady-state transdermal ﬂux for CLT loaded ET4 formu-
lation and TT3 formulation were observed to be 56.25 ±
5.49 lg/h/cm2 and 50.16 ± 3.84 lg/h/cm2, respectively. In
addition, the transdermal ﬂux of hydroethanolic solution and
plain drug solution was also investigated, and compared with
ethosomal and UL formulations, that revealed marked lower
ﬂux values (P< 0.05) and a higher lag time of 21.25 ±
1.04 lg/h/cm2, 1.8 h; and 1.20 ± 0.82 lg/h/cm2, 2.7 h
(Table 2).3.5. Vesicle skin interaction studies
Vesicle skin interaction studies of ET4 and TT3 formulations
(optimized formulations) exhibit no major alterations in the
skin histopathology. However, on application, mild swelling
of corneocytes and skin lipid ﬂuidization (penetrationn as seen by AFM (atomic force microscopy).
Figure 2B Photomicrographs of TT3 formulation as seen by AFM (atomic force microscopy).
Figure 3 FT-IR spectra of rat skin after 8 h. (A) Untreated skin,
(B) Hydroethanolic solution, (C) TT3 formulation, (D) ET4
formulation.
166 R.G.S. Maheshwari et al.pathways) were observed with ET4 formulation, whereas only
slight pufﬁness was observed in the case of TT3 formulation.These outcomes revealed the possible mechanisms of skin pen-
etration by these nanocarriers as also explored earlier (Touitou
et al., 2000; Cevc et al., 2002; Jain et al., 2004; Paolino et al.,
2005a,b; Elsayed et al., 2006; Paul et al., 1998).
3.6. Size distribution measurement
Investigation using Dynamic Light Scattering (DLS) revealed
smallest polydispersity index of ET4 formulation (0.0279 ±
0.019) and TT3 formulation (0.067 ± 0.009) with optimized
vesicle size of 132 ± 9.53 nm and 121.94 ± 9.78 nm, respec-
tively (Table 1). In addition, the vesicle size investigation by
TEM and AFM also shows good correlation with zetasizer
reports.
3.7. Evaluation of bilayer ﬂuidity using FT-IR spectroscopy
Alteration in the ﬂuidity of stratum corneum was observed by
focusing on the region near to 2850 cm1 and 2920 cm1 as
shown in Fig. 3. In the case of ET4 formulation, it may be
concluded that the peaks obtained near at 2850 cm1 and
2920 cm1 were due to the C–H symmetric stretching and
C-H asymmetric stretching absorbance, with slight alterations,
as shown in Table 3.
3.8. In vitro anticandidal testing
The outcomes show greater potential of vesicle systems (in
comparison to marketed cream formulation) in inhibiting the
Table 3 Alterations on the C–H symmetric and C–H asymmetric stretching absorbance shifts on the acyl chains of stratum corneum
lipids upon the application of different formulations.
Skin treatments C–H symmetric stretching (cm1) C–H asymmetric stretching (cm1)
Untreated 2850.18 ± 1.21 2920.11 ± 1.11
30% Hydroethanolic solution 2852.38 ± 1.10 2921.76 ± 1.21
TT3 formulation 2853.56 ± 0.78 2924.42 ± 0.97
ET4 formulation 2854.89 ± 1.15 2925.12 ± 1.12
Values are represented as mean ± SD (n= 3).
Table 4 In vitro anticandidal activity of different formulations
using disk diffusion method and C. albicans as the test
organism.
Formulations Inhibition zone (mm) Mean (mm) SD
Test I Test II Test III
Control 20 18 19 19.0 1.00
ET4 (Test I) 34 35 35 34.6 0.57
TT3 (Test II) 30 29 30 29.6 0.57
Values are represented as mean ± SD (n= 3).
Table 2 Transdermal ﬂux (lg/h/cm2) and lag time (h) of ET4, TT3, Hydroethanolic solution and plain drug solution.
Parameters ET4 TT3 Hydroethanolic solution (45%) Plain drug solution (1% CLT)
Transdermal ﬂux (lg/h/cm2) 56.25 ± 5.49 52.16 ± 3.84 21.25 ± 1.04 1.20 ± 0.82
Lag time (h) 0.9 1.0 1.8 2.7
Values are represented as mean ± SD (n= 3).
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in vitro anticandidal testing given in Table 4. The aver-
age ± SD inhibition zone values of the test formulations (Test
I, ET4 and Test II, TT3), and control formulation (marketed
cream) were found to be 34.6 ± 0.57 mm, 29.6 ± 0.57 mm,
and 19.0 ± 1.00 mm, respectively. From the above mentioned
results and by comparing the inhibition zone of the test formu-
lations with the control, it was concluded that ET4 and TT3 for-
mulations showed much better inhibitions, although the ET4
and TT3 formulations were signiﬁcantly different (P< 0.001)
from each other, as conﬁrmed using the Student t-test.
4. Discussion
4.1. Formulation, optimization and entrapment efﬁciency (EE)
We aimed at exploring the opportunities toward transdermal
delivery of CLT by modifying lipid membrane composition
(Ethosomes and ultradeformable liposomes), with the speciﬁc
objective to predict surface characteristics and carrier efﬁ-
ciency following topical administration, and thereby compar-
ing the two established approaches.
Initially, formulation/optimization of ethosomal and UL
formulations were done on the basis of entrapment efﬁciency
and vesicular size/characteristic analysis, wherein it was found
that the ethosomal formulation ET4 and UL formulation TT3
possess loading potential of higher order and smallest vesicle
size, as shown in the Table 1. Our optimizations are in accor-dance with the observations of the other scientiﬁc groups (Cevc
et al., 2002; Lopez-Pinto et al., 2005; Dubey et al., 2007a,b;
Mahor et al., 2007).
Furthermore, on comparative assessment of data, a better
entrapment efﬁciency was observed in the case of ET4
(68.73 ± 1.4%) in comparison to TT3 (65.51 ± 1.7%) and this
could be attributed to better solubility and retentivity of CLT
in ethanol present in the ethosomal core, rather than in phos-
phate buffer pH 7.4, which was engaged as hydration medium
during the preparation of TT3 formulation (Touitou et al.,
2000; Jain et al., 2004; Paolino et al., 2005a,b; Elsayed et al.,
2006; Paul et al., 1998).
In terms of vesicle size examination, on increasing the con-
centration of ethanol and surfactant, in the ethosomal and UL
formulations, an obvious decrease in vesicle size was observed
to a signiﬁcant level (P< 0.01). In the case of ethosomal for-
mulations with ethanol concentration ranging from 15 to 45%,
the size of the vesicles decreased with increase in ethanol con-
centration. The formulation containing 45% ethanol showed
smaller size (132 ± 9.5 nm) as compared to that of formula-
tion containing 15% ethanol (163 ± 13 nm). On another side,
in the case of UL formulations, the vesicle size of the systems
embedded with 5–20 parts of surfactant showed an increase in
average vesicle size, but to some degree, as in our case, the for-
mulation containing 15 parts of surfactant showed lowest ves-
icle size (121 ± 9.7 nm) and the system containing 20 parts of
surfactant showed further increases in the vesicle size
(184 ± 12 nm). On comparative background, the decrease in
vesicle size of ethosomal formulations with increasing ethanol
concentration was predominantly assumed to be a function of
membrane thickness; wherein considerable reduction in mem-
brane thickness was observed with increase in ethanol concen-
tration (P< 0.01). This might be due to the formation of
hydrocarbon phase with inter-penetrating properties, an obser-
vation experienced by a number of scientiﬁc groups (Touitou
et al., 2000; Dubey et al., 2007a,b), whereas in the case of
UL formulations, increase in span-80 concentration resulted
in decrease in vesicle size of the system, might be due to its sur-
face active properties (provides elasticity) and membrane soft-
ening/reduction ability. An increased vesicle size (184 ±
12 nm) and decreased entrapment efﬁciency (42.3 ± 1.4%)
Figure 4 Comparative cumulative amount of CLT permeated
from ET4 formulation, TT3 Formulation, hydroethanolic solution
and plain drug solution in a 24 h study via abdominal rat skin.
168 R.G.S. Maheshwari et al.was observed in the UL formulation containing 20 parts of
surfactant (TT4), attributing to the reduction in the net charge
of the vesicle system (Mahor et al., 2007).
4.2. TEM and AFM measurements
Both the formulations (ET4 and TT3) conﬁrm the formation of
vesicular structure, spherical shape and mostly unilamellar
arrangement, as characterized by TEM. Speciﬁcally, ethosomal
formulation (ET4) showed a more imperfect round shape, when
compared with UL formulation (TT3), explaining the ﬂuidizing
effect of ethanol, a phenomenon observed earlier (Touitou et al.,
2000). The surface morphology and topography revealed by
TEM measurements were further conﬁrmed by investigation
using AFM. The data (shape, structure, surface morphology
and sizemeasurement) obtained usingAFM(Fig. 4) clearly indi-
cate regarding the surface properties of formulations.
4.3. Size distribution measurement
Dynamic light scattering, allowed determining the vesicle size as
well as the size distribution. The smallest polydispersity index ofFigure 5A Model schematic for skinET4 formulation (0.027 ± 0.019) and TT3 formulation
(0.067 ± 0.009) revealed their homogeneous distribution in ves-
icle systems; and optimized vesicle size of ET4 formulation
(132 ± 9.5 nm) andTT3 formulation (121.94 ± 9.7 nm) are evi-
dence of their nanometric size range, thereby an overall better
permeation proﬁle was obtained. (Table 1).
4.4. Skin permeation studies
Delivery rates of CLT loaded vesicles were investigated by
determining the transdermal ﬂux of CLT across excised
abdominal rat skin. In comparison to hydroethanolic solution
and plain drug solution (21.25 ± 1.04 lg/h/cm2 1.8 h and
1.20 ± 0.82 lg/h/cm2, 2.7 h; respectively); ET4 and TT3 for-
mulations (56.25 ± 5.49 lg/h/cm2, 0.9 h and 52.16 ± 3.84
lg/h/cm2, 1.0 h; respectively) attained greater transdermal ﬂux
and lower lag time as well. (Paolino et al., 2005a,b; Lodzki
et al., 2003; Kirjavainen et al., 1996) On further comparison,
the enhanced permeation with ET4 formulation could be
attributed to ethanol content in the ethosomal core (Touitou
et al., 2000), whereas, the driving force for the TT3 formulation
entering the skin were xerophobia (tendency to avoid dry
surroundings) and the naturally occurring in vivo transcutaneous
hydration gradient (Cevc et al., 2002; Dubey et al., 2006;
Elsayed et al., 2007; Muzzalupo et al., 2008). Our ﬁndings
are in good agreement with the earlier reported (Ebtessam
et al., 2004; Dubey et al., 2007a,b; Kim et al., 1992).
4.5. Vesicle skin interaction studies
Furthermore, in contrast to TT3 formulation, accumulations
in the top layer of the skin with no signiﬁcant ultra structural
changes were observed only with the skin treated with ET4 for-
mulation, exploring the partial lipid extraction mechanism and
skin lipid ﬂuidization capability of ethanol (Fig. 5A) (Jain
et al., 2007), whereas, a slight pufﬁness of corneocytes, in the
case of TT3 formulation was observed and might be due to
the stress-dependent adaptability, which enables them alone
to squeeze between the cells in the skin, also indicating the
presence of surfactant in the UL formulation (Cevc et al.,
2002). Our ﬁndings clearly justify the potential of ethanol, to
extract and ﬂuidize the skin lipid, which leads to the formationdelivery from ethosomal system.
Figure 5B Ultradeformable transfersomes compressing through minute pores in the Stratum corneum.
Ethosomes and ultradeformable liposomes for transdermal delivery of clotrimazole 169of small pores, in forms of penetration pathways, further jus-
tifying the integrity of ethosomes, over ultradeformable lipo-
somes (Fig. 5B).
4.6. Evaluation of bilayer ﬂuidity using FT-IR spectroscopy
An investigation of lipid bilayer mobility was carried out using
FT-IR spectroscopy, using the abdominal portion of rat skin. In
comparison to TT3 formulation, ET4 formulation showed high-
er broadening of peaks near 2920 cm1, whichwas an indication
of an increase in the ﬂuidity of lipid bilayer, probably due to po-
sitive alterations in lipid acyl chain with increasing rotational
freedom. Furthermore, the push effect (increase in thermody-
namic activity due to ethanol evaporation from vesicle system),
and pull effect (reduction in barrier properties) of ethanol are
responsible for generating an increase of peaks near 2850 cm
1 and broadening of peaks near at 2920 cm1, which could be
attributing to enhanced penetration and permeability, as well.
These outcomes clearly indicate the disruption of lipid arrange-
ment in lipid bilayer organization, which is lacking in rest of the
formulations, probably due to the absence of ethanol. Results
are analogous to that reported earlier (Dubey et al).
4.7. In vitro anticandidal testing
In addition, the inhibition zone value of Test I (34.6 ±
0.57 mm), suggested that the ET4 formulation exhibited better
in vitro anticandidal activity against C. albicans in comparison
with Test II (29.6 ± 0.57 mm) and control (19.0 ± 1.00 mm)
formulations. It was found that the test I was signiﬁcantly dif-
ferent from test II and control (P< 0.01 in both cases), So it
can be concluded that the ethanol containing formulation
exhibited better anticandidal activity than the surfactant con-
taining formulation, probably due to the extra potential of eth-
anol to kill organisms by denaturing their proteins and
dissolving their lipids, apart from skin ﬂuidization and pene-
tration (McDonnell and Russell, 1999). From this study, it
can be concluded that the ethanol containing formulation is
the better carrier system and is a therapeutically promising
candidate for the efﬁcient skin delivery of CLT, over surfac-
tant based formulation.5. Conclusion
Our results of transdermal ﬂux, bilayer ﬂuidity measurement,
entrapment efﬁciency and in vitro anticandidal testing suggest
better aptness of CLT with ethosomal formulation, instead ofUL formulation, might be due to greater solubility, retentivity,
and adaptability in lipid bilayers consisting of ethanol. This re-
search in particular may shed new light toward ongoing re-
search toward the development of effective formulation for
enhanced transdermal delivery particularly in the case of skin
ailments like Acneiform eruptions, Chronic blistering, Derma-
titis, Epidermal nevi, neoplasms, cysts, Parasitic infestations,
Lichenoid eruptions, Mucinoses, Pruritic, Psoriasis etc.Acknowledgements
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